Goodison Park saved from bulldozers to become home of Everton Women
Goodison Park, one of the UK's oldest football stadiums, has been saved from demolition and will become the country's first major stadium dedicated solely to a women's team next season.
Hailed as a gamechanging move for women's football, Everton Women will kick off their first season at Goodison in September, 133 years after the men's team started playing at the ground in Walton, Liverpool.
Goodison, which has hosted more top-flight games than any other stadium in England since it became the home of Everton football club in 1892, was set to be bulldozed when the men's side move to a new 52,888-seat stadium in Bramley-Moore dock on the banks of the Mersey next season. Sunday's game against relegated Southampton will mark Goodison's last Premier League fixture.
Related: David Squires on … the many memories of Everton's Goodison Park
But in a shock move that has delighted fans the club's new American owners have announced that the historic ground will become the new long-term home of the women's team in a bid to make the ground 'one of the most distinctive homes in European women's football'.
The move would provide 'a blueprint for how clubs can build the future of women's football', said Nikki Doucet, the CEO of Women's Super League Football. 'Establishing Goodison Park as a purpose-driven home for the women's team sends a powerful signal – not just about ambition, but about belief,' she said. 'Belief in the players, the fans, and in what the women's game can become when given the stage it deserves.'
Everton Women are currently in eighth position in the WSL, but sources said the move was a 'statement of intent' of the new owners' ambitions for the women's team. The Friedkin Group, owned by the Texas billionaire Dan Friedkin, bought Everton in December last year, bringing the turbulent era of Farhad Moshiri to an end.
After the group took over AS Roma in 2020, the women's team came fifth in the 2020-21 season and took their first major trophy, winning the 2021 Coppa Italia. They won their first Serie A title in 2023, and secured the domestic double in 2024.
'It shows just how committed they are to backing the women's team and making Everton a force at the very top of the women's game in this country,' said Julie Makin, secretary of the Everton Women Supporters' Club.
Everton Women's tenure at Goodison Park comes 105 years after the ground hosted a landmark women's match between Dick, Kerr Ladies and St Helens Ladies, which held the attendance record for a women's game for 103 years. 'Evertonians have a saying of 'If you know your history', that is why it is deeply meaningful that the very same ground that held the record attendance for a women's fixture for so many years will now become home to Everton Women,' said Richie Gillham, secretary of the Everton FC Heritage Society.
Sources at the club said Everton Women's move from Walton Hall Park, which has a capacity of just 2,220, was seen as an financial opportunity for the club to increase attendances at women's games. The WSL is expected to attract 1 million fans for the first time this season, with attendances doubling in the last two seasons. With more than half of those attending games under 40, the club hopes to build lifelong loyalty at a venue which already has a significant sentimental draw. 'This move is a testament to where the women's game is right now and, more importantly, where it is heading,' said Everton Women's captain, Megan Finnigan.
A feasibility study commissioned by The Freidkin Group last month confirmed that the ground would meet standards set by the WSL, but the Archibald Leitch-designed stadium is likely to change dramatically after its new custodians move in.
'We know how treasured Goodison is, not only to every Evertonian, but to the game itself,' said Everton's recently appointed CEO, Angus Kinnear. 'We're under no illusions – there are obstacles we need to overcome to make this a success, but we're confident that we will overcome those challenges.'
Everton will drastically reduce its 39,000 capacity – with upper tiers of the ground likely to be taken out of action after season ticket seats are sold off to fans at the end of this season. But there are no immediate plans to change its structure in the short term, according to the club which added that it was 'planning targeted investments' to adapt the ground for the women's game.
It is understood that plans drawn up under the club's previous owners, to bulldoze Goodison to make way for a community-focused regeneration project with housing, shops, a care home and healthcare facilities, have become less viable since they were first submitted in April 2020. But the club's charitable arm Everton in the Community, which runs outreach work in the mile radius of Goodison, will be based at the ground, with the charity developing plans to support the development of girls' and women's football more widely.
'What we are looking to do with the women and girls strategy at Goodison Park is really exciting,' said Sue Gregory, the CEO of the charity. 'But for our communities I think its important that when they come down the County Road they will still see Goodison and feel the presence of the club.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera ( in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA. The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that it has established a wholly owned subsidiary, Immuthera, a United States C Corporation, in the state of Delaware. This is a further step by PolTREG to deepen its entry into the U.S. market. 'Over recent years, PolTREG has created a platform for the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, mulit-eidited/allogeneic CAR-Tregs, antigen-specific Tregs, and mRNA immunotherapies, all informed by our clinical experience. To fully leverage our potential, we are focusing on the execution our growth strategy in the American market by systematically bringing existing therapies, and exploring new assets into the US. We have established partnerships with several renowned entities such as Noble Capital Markets, Inc., for strategic and financial advisory services. We have also formed a strategic cooperation with the Swiss company Antion Biosciences to develop the next generation of allogeneic TREG therapies' said Prof. Piotr Trzonkowski, CEO of PolTREG. 'This expands PolTREG's project pipeline and enhances the company's attractiveness to potential strategic partners. Additionally, we with the U.S. company Kinexum Services LLC for strategic advisory regarding Immuthera's interactions with the FDA and the registration of TREG therapies in the United States. We submitted our Pre-IND meeting request to the FDA in mid-May,' added Prof. Piotr Trzonkowski. PolTREG is currently in discussions with leading American academic and clinical centers to establish collaborations and evaluate new technologies Immuthera has also begun the process of building a world-class Scientific Advisory Board comprised of globally recognized leaders in the Autoimmune and Neuroinflammatory disease. In support of PolTREG and the launch of Immuthera, Dr. Dan Shelly, Chief Business Development Officer, and Dr. Mariusz Jablonski, Chief Business Officer, will participate in the upcoming BIO International Convention 2025, taking place from June 16–19 in Boston. At BIO Drs. Shelly and Jablonski will be promoting PolTREG's current clinical and developmental pipeline while also speaking to potential partners, collaborators, and investors for Immuthera. In May, the Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on the Pediatric Investigation Plan (PIP) for PolTREG's investigational somatic cell therapy product, polyclonal Treg lymphocytes (PTG-007), which is aimed to prevent symptomatic type 1 diabetes in children. The PDCO's positive opinion is based on PolTREG's original preTreg clinical trial protocol, initiated in October 2024, enrolling children aged 6–16 years with Stage 1 type 1 diabetes. In its assessment, the committee recommended broadening the eligible population to include patients aged 3–18 years suggesting that the agency believes this therapy is extremely safe. This positive opinion paves the way for potential marketing authorization in the EU. To read more about the clinical trials PolTREG has completed, please click on: PolTREG manufactures its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe's largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines. PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours. About PolTREG PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For more information please visit For further information please contact:PolTREG Piotr TrzonkowskiChief Executive Officerir@ 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Yahoo
30 minutes ago
- Yahoo
Real Matters Inc.'s (TSE:REAL) top owners are retail investors with 60% stake, while 35% is held by institutions
Significant control over Real Matters by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 41% ownership Institutional ownership in Real Matters is 35% Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Real Matters Inc. (TSE:REAL) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 60% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Institutions, on the other hand, account for 35% of the company's stockholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. In the chart below, we zoom in on the different ownership groups of Real Matters. Check out our latest analysis for Real Matters Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. Real Matters already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Real Matters' historic earnings and revenue below, but keep in mind there's always more to the story. We note that hedge funds don't have a meaningful investment in Real Matters. FMR LLC is currently the largest shareholder, with 10% of shares outstanding. With 10% and 5.0% of the shares outstanding respectively, Manitou Investment Management Ltd. and Jason Smith are the second and third largest shareholders. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Real Matters Inc.. In their own names, insiders own CA$22m worth of stock in the CA$422m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a substantial 60% stake in Real Matters, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. It's always worth thinking about the different groups who own shares in a company. But to understand Real Matters better, we need to consider many other factors. Be aware that Real Matters is showing 1 warning sign in our investment analysis , you should know about... If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Zverev into Stuttgart semis, Auger-Aliassime stops teenager Engel
German tennis player Alexander Zverev in action against USA's Brandon Nakashima at their quarter-final tennis match during day five of the BOSS Open tennis tournament. Marijan Murat/dpa Top seed Alexander Zverev reached the Stuttgart Open semi-finals on Friday, and so did Felix Auger-Aliassime by stopping German teenager Justin Engel. Zverev defeated American Brandon Nakashima 7-5, 6-4 in one and a half hours. His next opponent will be either another American in Ben Shelton or Czech Republic's Jiri Lehecka. Advertisement "It was a good match for the second one on grass court. Today's level was better than yesterday," he said referring to his last 16 game against Corentin Moutet on Thursday. "I'm happy to have served the way I did," he added. Auger-Aliassime beat the 17-year-old Engel 7-6 (7-3), 6-3. The two traded breaks midway through the first set, and Canada's Auger-Aliassime then won the final three games for victory in 1:38 hours which he clinched with his 18th ace. He next faces second seed Taylor Fritz, who broke Hungary's Marton Fucsovics once in each set and fired 14 aces en route to a 6-3, 6-4 quarter-final victory in 1 hour 15 minutes. Advertisement Wildcard entry Engel, who is ranked 281st, was playing his first career quarter-final on the ATP Tour. At age 17 he was the youngest player in the last eight of a grass court tournament since Boris Becker's run to his first Wimbledon title 40 years ago in 1985. "My takeaway is that I can keep up with the top guys and that the hard training is paying off. Now I'll just keep going," Engel said. The Stuttgart Open is one of tune-up tournaments for Wimbledon, which starts on June 30. German tennis player Alexander Zverev in action against USA's Brandon Nakashima at their quarter-final tennis match during day five of the BOSS Open tennis tournament. Marijan Murat/dpa
